Bayer has announced that it has stopped a trial of Nexavar (sorafenib) in patients with non-small cell lung cancer, because the drug didn't improve survival.
The company said the drug's safety profile was the same as in earlier studies, but deaths were higher in one group of patients. Bayer and its partner Onyx Pharmaceuticals are analysing the data to decide on the drug's use in other types of lung cancer.
0
Like
0
Love
0
Angry
0
Dislike
0
